BioAdvance News Portfolio News Venatorx Pharmaceuticals

Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022

By WebmasterOctober 20, 2022November 1st, 2024No Comments

Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022

Superior to Meropenem for the Primary Efficacy Endpoint

Safety Profile Consistent with Meropenem

Previous PostSenzo Receives Funding from the Biomedical Advanced Research and Development Authority (BARDA) to Advance Its PCR-Accurate Lateral Flow COVID-19 Test
Next PostTreventis Awarded $2.97M Grant from the U.S. Department of Defense